Bausch + Lomb Corp. announced an amendment to the employment agreement with its CEO, Brenton L. Saunders, on July 21, 2025. The amendment modifies Mr. Saunders' "good reason" severance rights related to the company's spin-off from Bausch Health Companies Inc. Additionally, the terms of Saunders' performance stock units have been revised. These units will now vest and payout between 120% and 330% of the target by February 23, 2029, based on achieving specific share-price hurdles and a new cumulative Adjusted EBITDA performance goal for the fiscal years 2025-2028. The full text of these amendments will be available in the company's upcoming Quarterly Report on Form 10-Q.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.